Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (Bi-sdAb) is designed to be expressed as a VHH from anti-CD28 antibody variable domains fused with a VHH from an anti-EGFR antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD28 VHH x Anti-EGFR VHH BispecificAntibody (Bi-sdAb) (BIVHH-012). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS